Analyst Price Targets — TVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 12:16 pm | — | Evercore ISI | $78.00 | $61.74 | TheFly | Travere Therapeutics price target raised to $78 from $68 at Evercore ISI |
| August 6, 2026 11:06 am | — | Canaccord Genuity | $70.00 | $62.76 | TheFly | Travere Therapeutics price target raised to $70 from $62 at Canaccord |
| June 25, 2026 11:38 am | Vamil Divan | Guggenheim | $65.00 | $59.40 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $65 at Guggenheim |
| June 2, 2026 3:38 pm | Joseph Pantginis | H.C. Wainwright | $67.00 | $42.96 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $67 at H.C. Wainwright |
| April 14, 2026 3:15 pm | — | Piper Sandler | $49.00 | $41.11 | TheFly | Travere Therapeutics upgraded to Overweight from Neutral at Piper Sandler |
| April 14, 2026 11:34 am | — | Guggenheim | $54.00 | $30.70 | TheFly | Travere Therapeutics price target raised to $54 from $49 at Guggenheim |
| January 14, 2026 11:48 am | Vamil Divan | Guggenheim | $49.00 | $28.39 | StreetInsider | Guggenheim Reiterates Buy rating and Best Idea on Travere Therapeutics (TVTX) |
| September 10, 2025 2:48 pm | Maury Raycroft | Jefferies | $35.00 | $27.31 | TheFly | AdCom cancellation 'clear positive' for Travere Therapeutics, says Jefferies |
| October 31, 2024 8:21 pm | Liisa Bayko | Evercore ISI | $33.00 | $17.50 | StreetInsider | Travere Therapeutics (TVTX) PT Raised to $33 at Evercore ISI |
| October 21, 2024 5:38 am | Mohit Bansal | Wells Fargo | $27.00 | $17.87 | StreetInsider | Wells Fargo Upgrades Travere Therapeutics (TVTX) to Overweight |
Latest News for TVTX
Artia Global Partners LP purchased a new stake in Travere Therapeutics, Inc. (NASDAQ: TVTX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 339,033 shares of the company's stock, valued at approximately $19,260,000. Travere Therapeutics accounts for about 3.6% of
Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. FILSPARI's commercial ramp is strong, posting $141.1M in Q2 U.S. sales and targeting a $3B+ peak sales opportunity across IgAN and FSGS. My model assumes modest FILSPARI penetration, conservative pricing, and accounts for royalty burdens, tax credits, and IP risks.
HONG KONG, Aug 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered
Travere Therapeutics NASDAQ: TVTX is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building its renal pipeline through the recently in-licensed BTK inhibitor civorebrutinib, Chief Financial Officer Chris Cline said at a Canaccord Genuity discussion.
Bank of America Corp DE lessened its holdings in shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) by 27.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,345,111 shares of the company's stock after selling 517,244 shares
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TVTX.
U.S. House Trading
No House trades found for TVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.